Real-world post-authorization effectiveness study (PAES) of pembrolizumab for the treatment of NSCLC across races, ethnicities, and age groups (MK-3475-G18)

03/06/2025
16/01/2026
EU PAS number:
EUPAS1000000576
Study
Ongoing
Subscribe
Download as PDF
Documents
Study protocol
Initial protocol

MK-3475-G18-00-v3-Protocol_final-redaction.pdf

English (398.56 KB - PDF) View document
Study results
Study report
Other information